BioAge Labs Inc. (BIOA)
| Bid | 4.42 |
| Market Cap | 162.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -727.71M |
| EPS (ttm) | -6.63 |
| PE Ratio (ttm) | -0.68 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 4.58 |
| Volume | 146,763 |
| Avg. Volume (20D) | 247,465 |
| Open | 4.37 |
| Previous Close | 4.49 |
| Day's Range | 4.31 - 4.62 |
| 52-Week Range | 3.85 - 26.62 |
| Beta | 1.14 |
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clin...
Analyst Forecast
According to 4 analyst ratings, the average rating for BIOA stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 10.13% from the latest price.
Stock Forecasts
2 weeks ago · accessnewswire.com
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIOANEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities la...
